Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors

Journal:
Nature
Published:
DOI:
10.1038/s41586-025-09433-w
Affiliations:
11
Authors:
59
Go to article
Institutions Authors Share
Circle Pharma, United States of America (USA)
36.000000
36.000000
36.000000
36.000000
 0.61
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
11.000000
11.000000
 0.19
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)
4.000000
 0.07
Brigham and Women's Hospital (BWH), United States of America (USA)
4.000000
 0.07
University of Oxford, United Kingdom (UK)
3.000000
 0.05
Broad Institute of MIT and Harvard, United States of America (USA)
1.000000
 0.02
Interested in Oncology and Carcinogenesis?